and prevent structure initiating events in the di-proline to be propagated into the candidate peptide structure. Thus, preferred stability sequences are as follows: $MG(X)_nGGPP$ (SEQ ID NO:7), where X is any amino acid and n is an integer of at least four.--

On page 68, immediately preceding the heading "CLAIMS", please insert the enclosed text entitled "SEQUENCE LISTING."

REMARKS

The specification has been amended to include a Sequence Listing and proper reference to the sequences therein. Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached pages are captioned "Version With Markings to Show Changes Made."

Entry of this amendment is respectfully requested. The amendments are made in adherence with 37 C.F.R. § 1.821-1.825. This amendment is accompanied by a floppy disk containing the above named sequence listing, SEQUENCE ID NUMBERS 1-7, in computer readable form (CRF), and a paper copy of the sequence information. The computer readable sequence listing was prepared through use of the software program "PatentIn" provided by the PTO. The sequence listing information contained in the computer readable disk is identical to that of the paper copy. This amendment contains no new matter. Applicant submits that this amendment, the accompanying computer readable sequence listing, and the paper copy thereof serve to place this application in a condition of adherence to the rules 37 C.F.R. § 1.821-1.825.

Please direct any calls in connection with this application to the undersigned at (415) 781-1989.

Respectfully submitted,

FLEHR HOHBACH TEST
ALBRITTON & HERBERT LLP

Dated: 12/19/01

Four Embarcadero Center
Suite 3400
San Francisco, CA 94111-4187
Telephone: (415) 781-1989

Renee M. Kosslak, Reg. No. 47,717 for
Robin M. Silva, Reg. No. 38,304

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

The table beginning at page 37, line 13, has been amended as follows:

–

	1	2	3	4	5	6	7	8	9	10	11	12	SEQ ID NO:
1	LEU	LEU	ILE	ILE	ALA	LEU	LEU	LEU	LEU	PHE	ALA	LEU	1
2	LEU	LEU	ILE	ILE	ALA	LEU	LEU	LEU	LEU	ILE	ALA	LEU	2
3	LEU	LEU	ILE	ILE	ALA	LEU	LEU	LEU	LEU	ILE	ALA	LEU	2
4	LEU	LEU	ILE	ILE	ALA	LEU	LEU	LEU	LEU	PHE	ALA	ILE	3
5	LEU	LEU	ILE	ILE	ALA	LEU	LEU	LEU	LEU	PHE	ALA	ILE	3
6	LEU	LEU	ILE	ILE	ALA	LEU	LEU	LEU	LEU	ILE	ALA	ILE	4
7	LEU	LEU	ILE	ILE	ALA	LEU	LEU	LEU	ILE	PHE	ALA	LEU	5
8	LEU	LEU	ILE	ILE	ALA	LEU	LEU	LEU	LEU	ILE	ALA	ILE	4
9	LEU	LEU	ILE	ILE	ALA	LEU	LEU	LEU	ILE	PHE	ALA	LEU	5
10	LEU	LEU	ILE	ILE	ALA	LEU	LEU	LEU	LEU	LEU	ALA	LEU	6

–

Paragraph beginning at page 46, line 30, has been amended as follows:

– In a preferred embodiment, the fusion partner is a stability sequence to confer stability to the library member or the nucleic acid encoding it. Thus, for example, peptides may be stabilized by the incorporation of glycines after the initiation methionine (MG or MGG0), for protection of the peptide to ubiquitination as per Varshavsky's N-End Rule, thus conferring long half-life in the cytoplasm. Similarly, two prolines at the C-terminus impart peptides that are largely resistant to carboxypeptidase action. The presence of two glycines prior to the prolines impart both flexibility

and prevent structure initiating events in the di-proline to be propagated into the candidate peptide structure. Thus, preferred stability sequences are as follows: $MG(X)_nGGPP$ (SEQ ID NO:7), where X is any amino acid and n is an integer of at least four.–

On page 68, immediately preceding the heading "CLAIMS", the enclosed text entitled "SEQUENCE LISTING" was inserted into the specification.